BIO bemoans lack of investment in cardio disease research

7 February 2020

In the USA, 96.1 million people suffer from hypertension, and another 5.8 million from heart failure. However, investment in new therapies for these chronic diseases is not growing at the rates needed to keep up with the impact they have on human health or the economy, says the latest report from the Biotechnology Innovation Organization (BIO) industry analysis team.

The BIO Industry Analysis team’s new report, The State of Investment and Innovation in Hypertension and Heart Failure, is the fifth in a series on the innovation landscape of highly prevalent, chronic diseases.

Cardiovascular disease costs the American health care system more than twice as much as cancer ($275 billion versus $125 billion, respectively), but over the last 10 years, there has been 13 times more investment in cancer treatments ($15.5 billion) than cardiovascular therapies ($1.2 billion).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK